Wall Street analyst estimates for Atea Pharmaceuticals, Inc. (AVIR): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV).
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-11 | $-0.51 | ||
| 2026-08-12 | $-0.41 | $-0.56 | +26.1% |
| 2026-05-12 | $-0.57 | $-0.60 | +5.0% |
| 2026-03-05 | $-0.57 | $-0.49 | -16.3% |
| 2025-11-12 | $-0.53 | $-0.46 | -15.2% |
| 2025-08-07 | $-0.44 | $-0.46 | +4.3% |
| 2025-05-12 | $-0.40 | $-0.56 | +28.6% |
| 2025-03-06 | $-0.40 | $-0.35 | -14.3% |
Valuation Ratios
| Price / Book | 1.84 |
| EV / EBITDA | -2.04 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | $48.6M | $351.4M | 0 | 0 | 0 | 0 |
| Cost of Revenue | $17000 | $17000 | $38.0M | $167.2M | $62.4M | $70.1M | $83.4M | 0 |
| Gross Profit | -$17000 | -$17000 | $10.6M | $184.2M | -$62.4M | -$70.1M | -$83.4M | 0 |
| Research & Development | $6.7M | $10.2M | $38.0M | $167.2M | $88.8M | $132.8M | $145.4M | $148.0M |
| Selling, General & Admin | $2.8M | $4.4M | $21.6M | $45.8M | $48.7M | $49.9M | $48.8M | $32.9M |
| Operating Expenses | $9.5M | $14.6M | $21.6M | $45.8M | $68.3M | $94.1M | $109.6M | $180.9M |
| Operating Income | -$9.5M | -$14.6M | -$11.0M | $138.4M | -$130.7M | -$164.2M | -$192.9M | -$180.9M |
| EBITDA | -$9.5M | -$14.6M | -$11.0M | $138.6M | -$110.8M | -$119.6M | -$131.8M | -$164.1M |
| Interest Expense | 0 | 0 | 0 | 0 | $11.2M | 0 | 0 | 0 |
| Pre-tax Income | -$9.1M | -$14.0M | -$10.9M | $138.6M | -$119.5M | -$134.9M | -$167.5M | -$164.5M |
| Income Tax | 0 | 0 | 0 | $17.4M | -$3.6M | $1.0M | $925000 | -$6.2M |
| Net Income | -$9.1M | -$13.5M | -$10.9M | $121.2M | -$115.9M | -$136.0M | -$168.4M | -$158.3M |
| EPS | $-0.90 | $-0.16 | $-0.13 | $1.46 | $-1.39 | $-1.63 | $-2.00 | $-1.94 |
| EPS (Diluted) | $-0.90 | $-0.16 | $-0.13 | $1.37 | $-1.39 | $-1.63 | $-2.00 | $-1.94 |
| Shares Outstanding (Diluted) | $10.1M | $82.6M | $82.4M | $88.2M | $83.2M | $83.4M | $84.3M | $81.5M |
Price
| Price | $5.15 |
| Market Cap | $412M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ACHV · ALLO · ARCT · ENTA · HUMA · PYXS · TRDA
Explore sector: Healthcare · Biotechnology
More sections of AVIR: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks